Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 529-536

  Hirose, Takashi ^a,b   Fujita, Ken Ichi ^b   Nishimura, Kazuko ^c   Ishida, Hiroo ^b   Yamashita, Keishi ^b   Sunakawa, Yu ^b   Mizuno, Keiko ^b   Miwa, Keisuke ^b   Nagashima, Fumio ^b   Tanigawara, Yusuke ^c   Adachi, Mitsuru ^a   Sasaki, Yasutsuna ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Cancer; CYP2A6 genotype; Pharmacokinetics; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; CYTOCHROME P450 2A6; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE; CYP2A6 PROTEIN, HUMAN; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR; UNSPECIFIC MONOOXYGENASE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; COLON CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; FATIGUE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; GENETICS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHARMACOGENETICS; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2A6; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; OXONIC ACID; PHARMACOGENETICS; TEGAFUR;

EID: 77954361284     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000889     Document Type: Article

References (25)

1. Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1 M tegarur- 0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996. (Pubitemid 26171684)
2. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993. (Pubitemid 23267702)
3. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
4. Goto A, Yamada Y, Yasui K, et al: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17: 968-973, 2006.
5. Kawahara M, Furuse K, Segawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer. Br J Cancer 85: 939-943, 2001. (Pubitemid 33015993)
6. Evans WE and Mcleod HL: Pharmacogenomics - drug disposition, drug targets and side effects. N Eng J Med 348: 538-549, 2003.
7. Comets E, Ikeda K, Hoff P, Fumoleau P, Wanders J and Tanigawara Y: Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokin Pharmacodyn 30: 257-283, 2003.
8. Ajani JA, Faust J, Ikeda K, et al: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965, 2005.
9. Hirata K, Horikoshi N, Aiba K, et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000-2005, 1999.
10. Van Groeningen CJ, Peter GJ, Schornagel JH, et al: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18: 2772-2779, 2000.
11. Hoff PM, Saad ED, Ajani JA, et al: Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9: 134-142, 2003. (Pubitemid 36109725)
12. Ikeda K, Yoshisue K, Matsushima E, et al: Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6: 4409-4415, 2000.
13. Fujita K: Cytochrome P450 and anticancer drugs. Curr Drug Metab 7: 23-37, 2006.
14. Nakajima M, Fukami T, Yamanaka H, et al: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80: 282-297, 2006.
15. Nakajima M, Yoshida R, Fukami T, McLeod HL and Yokoi T: Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett 569: 75-81, 2004.
16. Ariyoshi N, Sawamura Y and Kamataki T: A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun 281: 810-814, 2001.
17. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT and Yokoi T: Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74: 69-76, 2003.
18. Matsushima E, Yoshida K, Kitamura R and Yoshida KI: Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxy-pyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative iron chemical ionization mass spectrometry. J Chromatogr B 691: 95-104, 1997.
19. Kochi M, Fujii M, Kanamori N, Kaiga T, Aizaki K, Takahashi T and Takayama T: Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in respectable gastric cancer patients. Cancer Chemother Pharmacol 60: 693-701, 2007.
20. Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H and Chida K: The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small cell lung cancer. Clin Pharmacol Ther 83: 589-594, 2008.
21. Tsuruoka Y, Kamano T, Kitajima M, et al: Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. Anticancer Drugs 17: 393-399, 2006.
22. Ikeda M, Furukawa H, Imamura H, et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 50: 25-32, 2002.
23. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effect of pyrimidine, barbituric acid and pyridine derivatives of 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987. (Pubitemid 17132408)
24. Nagashima F, Ohtsu A, Yoshida S and Ito K: Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8: 6-11, 2005.
25. Kong SY, Lim HS, Nam BH, et al: Association of CYP2A6 polymorphisms with S-1 plus docetaxle therapy outcomes in metastatic gastric cancer. Pharmacogenomics 10: 1147-1155, 2009.